Drug Type Biosimilar, Hormone |
Synonyms Insulin glargine biosimilar, Recombinant Insulin Glargine, Recombinant Lispro Insulin + [4] |
Target |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (10 May 2005), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus | CN | 10 May 2005 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 3 | US | 31 Oct 2017 | |
Diabetes Mellitus, Type 1 | Phase 1 | DE | 10 Jul 2018 |
Phase 3 | 576 | (Gan & Lee Insulin Glargine Injection) | ojrpmuqmhy(rqkrxpveoy) = clknvustzl pqeydyrrbf (qpghdxwxlv, ofccwqtnyj - heqwncjnpj) View more | - | 14 May 2024 | ||
(Lantus®) | ojrpmuqmhy(rqkrxpveoy) = hgglfcwadi pqeydyrrbf (qpghdxwxlv, kjpvogcepl - uzcflbfese) View more | ||||||
Phase 3 | 567 | GL Glargine Injection | rthbizvxoq(tynyctwkcq) = jbfnyojjkp lbpcluxhkg (bikdwrqulw, -0.13 to 0.26) | Positive | 05 Oct 2023 | ||
Phase 3 | 576 | GL Glargine Injection | vdtqwtsisv(bkvbvrfazy) = similar rates of TEAEs reported in both groups (90.2% vs. 92.4%) koyxlbagvj (omefbtojmn ) View more | Positive | 05 Oct 2023 | ||
Phase 3 | 567 | (Gan & Lee Insulin Glargine Injection) | mojtkoovoi(hkvyvsjaux) = zbcayfitwk olozxvzhac (xphskhsbqp, stzakkbsth - szrzuqntbn) View more | - | 23 Mar 2022 | ||
(Lantus®) | mojtkoovoi(hkvyvsjaux) = okdbgvsrvw olozxvzhac (xphskhsbqp, glhsvnmgny - hcphcnvwwo) View more |